|
US618965A
(en)
*
|
|
1899-02-07 |
|
Filter |
|
US2228904A
(en)
|
1939-05-10 |
1941-01-14 |
Bjorkman Hugo Leonard |
Wrench
|
|
WO1981001145A1
(en)
|
1979-10-18 |
1981-04-30 |
Univ Illinois |
Hydrolytic enzyme-activatible pro-drugs
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
GB8308235D0
(en)
*
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US6548640B1
(en)
*
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
AU595623B2
(en)
|
1986-05-29 |
1990-04-05 |
Ilexus Pty Ltd |
Fc receptor for immunoglobulin
|
|
GB8705477D0
(en)
|
1987-03-09 |
1987-04-15 |
Carlton Med Prod |
Drug delivery systems
|
|
JP3101690B2
(ja)
*
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
|
PT88641B
(pt)
|
1987-10-02 |
1993-04-30 |
Genentech Inc |
Metodo para a preparacao de uma variante de adesao
|
|
US5576184A
(en)
|
1988-09-06 |
1996-11-19 |
Xoma Corporation |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
|
US5681566A
(en)
|
1988-10-24 |
1997-10-28 |
3I Research Exploitation Limited |
Antibody conjugates with two or more covalently linked FC regions
|
|
US20040049014A1
(en)
|
1988-12-28 |
2004-03-11 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
JP3051411B2
(ja)
*
|
1989-03-14 |
2000-06-12 |
持田製薬株式会社 |
新規ｄｎａならびにそれを含有する発現プラスミド
|
|
US5266491A
(en)
|
1989-03-14 |
1993-11-30 |
Mochida Pharmaceutical Co., Ltd. |
DNA fragment and expression plasmid containing the DNA fragment
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
WO1991006305A1
(en)
|
1989-11-07 |
1991-05-16 |
Bristol-Myers Squibb Company |
Oligomeric immunoglobulins
|
|
US5859205A
(en)
*
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
AU7566991A
(en)
|
1990-03-14 |
1991-10-10 |
Biomembrane Institute, The |
Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
|
|
WO1991019515A1
(en)
|
1990-06-21 |
1991-12-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity
|
|
US5198342A
(en)
*
|
1990-07-05 |
1993-03-30 |
Immunex Corporation |
DNA encoding IgA Fc receptors
|
|
AU8506991A
(en)
|
1990-08-31 |
1992-03-30 |
Bristol-Myers Squibb Company |
Homoconjugated immunoglobulins
|
|
GB9022543D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
|
GB9022545D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Culture medium
|
|
GB9105245D0
(en)
|
1991-03-12 |
1991-04-24 |
Lynxvale Ltd |
Binding molecules
|
|
US6797492B2
(en)
*
|
1991-05-17 |
2004-09-28 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
|
WO1992022324A1
(en)
|
1991-06-14 |
1992-12-23 |
Xoma Corporation |
Microbially-produced antibody fragments and their conjugates
|
|
EP1400536A1
(en)
*
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5264586A
(en)
|
1991-07-17 |
1993-11-23 |
The Scripps Research Institute |
Analogs of calicheamicin gamma1I, method of making and using the same
|
|
US7018809B1
(en)
*
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
|
US5623053A
(en)
*
|
1992-01-10 |
1997-04-22 |
California Institute Of Technology |
Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
|
|
US5714350A
(en)
*
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5686072A
(en)
*
|
1992-06-17 |
1997-11-11 |
Board Of Regents, The University Of Texas |
Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
|
|
ES2156149T3
(es)
|
1992-12-04 |
2001-06-16 |
Medical Res Council |
Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
|
|
US5885573A
(en)
*
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
US20030108548A1
(en)
*
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
GB9316989D0
(en)
|
1993-08-16 |
1993-09-29 |
Lynxvale Ltd |
Binding molecules
|
|
AU707440B2
(en)
|
1994-03-29 |
1999-07-08 |
Celltech Therapeutics Limited |
Antibodies against E-selectin
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
WO1996003397A1
(en)
|
1994-07-21 |
1996-02-08 |
Akzo Nobel N.V. |
Cyclic ketone peroxide formulations
|
|
US5541087A
(en)
*
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
US6214388B1
(en)
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
EP1658772A3
(en)
|
1995-01-17 |
2007-01-17 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6086875A
(en)
*
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US5731168A
(en)
*
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
DE69536015D1
(de)
|
1995-03-30 |
2009-12-10 |
Pfizer Prod Inc |
Chinazolinone Derivate
|
|
US6121022A
(en)
*
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
US6444789B1
(en)
*
|
1995-05-03 |
2002-09-03 |
Applied Research Systems Ars Holding N.V. |
CD16-II variants
|
|
WO1996036360A1
(en)
|
1995-05-17 |
1996-11-21 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies
|
|
US6365161B1
(en)
*
|
1995-06-07 |
2002-04-02 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-FC receptor binding agents
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
|
ATE267610T1
(de)
|
1996-03-20 |
2004-06-15 |
Immunomedics Inc |
Glykosylierte igg antikörper
|
|
EA001595B1
(ru)
|
1996-04-12 |
2001-06-25 |
Варнер-Ламберт Компани |
Необратимые ингибиторы тирозинкиназ
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
WO1998002462A1
(en)
|
1996-07-16 |
1998-01-22 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Immunoglobulin superfamily domains and fragments with increased solubility
|
|
DE69738522T2
(de)
|
1996-08-02 |
2009-04-02 |
Bristol-Myers Squibb Co. |
Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
AU5927398A
(en)
|
1997-01-21 |
1998-08-07 |
Human Genome Sciences, Inc. |
Fc receptors and polypeptides
|
|
US6277375B1
(en)
*
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
DK0974111T3
(da)
*
|
1997-04-11 |
2003-04-22 |
California Inst Of Techn |
Apparat og metode til automatiseret design af proteiner
|
|
EP1255209A3
(en)
|
1997-04-11 |
2009-02-11 |
California Institute Of Technology |
Apparatus and method for automated protein design
|
|
US20020062010A1
(en)
*
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US20040191256A1
(en)
*
|
1997-06-24 |
2004-09-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
US6242195B1
(en)
*
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
US6194551B1
(en)
*
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
US7112324B1
(en)
*
|
1998-04-21 |
2006-09-26 |
Micromet Ag |
CD 19×CD3 specific polypeptides and uses thereof
|
|
DE19819846B4
(de)
*
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
|
EP1082137A4
(en)
*
|
1998-05-06 |
2004-05-19 |
Univ Temple |
REVERSE OF PERCENTAL RESPONSE BY INTERRUPTING THE MACROPHAGE RECEPTOR FcSg (g) RI
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
US6306926B1
(en)
*
|
1998-10-07 |
2001-10-23 |
3M Innovative Properties Company |
Radiopaque cationically polymerizable compositions comprising a radiopacifying filler, and method for polymerizing same
|
|
US20030049654A1
(en)
*
|
1998-10-16 |
2003-03-13 |
Xencor |
Protein design automation for protein libraries
|
|
AU774334B2
(en)
|
1998-10-16 |
2004-06-24 |
Xencor |
Protein design automation for protein libraries
|
|
US20020048772A1
(en)
*
|
2000-02-10 |
2002-04-25 |
Dahiyat Bassil I. |
Protein design automation for protein libraries
|
|
US7315786B2
(en)
*
|
1998-10-16 |
2008-01-01 |
Xencor |
Protein design automation for protein libraries
|
|
US6403312B1
(en)
|
1998-10-16 |
2002-06-11 |
Xencor |
Protein design automatic for protein libraries
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
WO2000067796A1
(en)
|
1999-05-07 |
2000-11-16 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
DE60042785D1
(de)
*
|
1999-06-09 |
2009-10-01 |
Immunomedics Inc |
Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
|
|
US6649165B2
(en)
|
1999-09-07 |
2003-11-18 |
Walter Schubert |
Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using soluble FcγRIII receptors
|
|
EP1229125A4
(en)
|
1999-10-19 |
2005-06-01 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING A POLYPEPTIDE
|
|
AU2048901A
(en)
|
1999-11-29 |
2001-06-04 |
Trustees Of Columbia University In The City Of New York, The |
Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
|
|
DE19958134C2
(de)
|
1999-12-02 |
2003-05-15 |
Koenig & Bauer Ag |
Saugwalze
|
|
US20060272036A1
(en)
|
2000-02-03 |
2006-11-30 |
Lennart Hammarstrom |
Ruminant mhc class-i-like fc receptors
|
|
EP1255826B1
(en)
|
2000-02-10 |
2005-09-14 |
Xencor |
Protein design automation for protein libraries
|
|
JP2003531588A
(ja)
*
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
|
JP2003531149A
(ja)
|
2000-04-13 |
2003-10-21 |
ザ・ロツクフエラー・ユニバーシテイ |
抗体由来の免疫応答の増強
|
|
US6358733B1
(en)
*
|
2000-05-19 |
2002-03-19 |
Apolife, Inc. |
Expression of heterologous multi-domain proteins in yeast
|
|
EP1296714B1
(en)
|
2000-06-22 |
2009-08-26 |
University Of Iowa Research Foundation |
Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
|
|
US20030013951A1
(en)
|
2000-09-21 |
2003-01-16 |
Dan Stefanescu |
Database organization and searching
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
CA2953239A1
(en)
|
2000-10-06 |
2002-04-18 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody composition-producing cell
|
|
CA2424977C
(en)
|
2000-10-06 |
2008-03-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
US6946292B2
(en)
*
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US7465790B2
(en)
|
2000-10-09 |
2008-12-16 |
Isis Innovation, Inc. |
Therapeutic antibodies
|
|
WO2002043658A2
(en)
*
|
2000-11-06 |
2002-06-06 |
The Jackson Laboratory |
Fcrn-based therapeutics for the treatment of auto-immune disorders
|
|
US7235643B2
(en)
|
2000-11-07 |
2007-06-26 |
Morphotek, Inc. |
Antibodies and methods for generating genetically altered antibodies with high affinity
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
US20040253242A1
(en)
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
|
US7083784B2
(en)
*
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
WO2002061090A2
(en)
|
2000-12-14 |
2002-08-08 |
Genentech, Inc. |
Prokaryotically produced antibodies and uses thereof
|
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
EP1358337A1
(en)
|
2001-01-30 |
2003-11-05 |
Degussa AG |
Nucleotide sequences which code for the otsa gene of c. glutamicum
|
|
CN100574803C
(zh)
*
|
2001-01-31 |
2009-12-30 |
拜奥根Idec公司 |
免疫调节抗体在治疗肿瘤性疾病中的用途
|
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
|
US20040136908A1
(en)
*
|
2001-04-09 |
2004-07-15 |
Olson William C. |
Anti-cd19 immunotoxins
|
|
US6989452B2
(en)
|
2001-05-31 |
2006-01-24 |
Medarex, Inc. |
Disulfide prodrugs and linkers and stabilizers useful therefor
|
|
GB0118662D0
(en)
*
|
2001-07-31 |
2001-09-19 |
Univ Southampton |
Binding agents
|
|
NZ571596A
(en)
|
2001-08-03 |
2010-11-26 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
WO2003016470A2
(en)
|
2001-08-10 |
2003-02-27 |
University Of Virginia Patent Foundation |
Enhancing the efficacy of immunotherapies by supplementing with complement
|
|
WO2003014325A2
(en)
|
2001-08-10 |
2003-02-20 |
Xencor |
Protein design automation for protein libraries
|
|
EP1293514B1
(en)
|
2001-09-14 |
2006-11-29 |
Affimed Therapeutics AG |
Multimeric single chain tandem Fv-antibodies
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
ES2283368T3
(es)
|
2001-11-14 |
2007-11-01 |
Affimed Therapeutics Ag |
Anticuerpos biespecificos anti-cd19 y anti-cd16 y usos de los mismos.
|
|
US6911321B2
(en)
*
|
2001-12-19 |
2005-06-28 |
Genentech, Inc. |
Non-human primate Fc receptors and methods of use
|
|
WO2003068801A2
(en)
|
2002-02-11 |
2003-08-21 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
|
US20040002587A1
(en)
*
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
US7317091B2
(en)
*
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20080260731A1
(en)
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
US20040132101A1
(en)
*
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
JP2005526769A
(ja)
|
2002-03-15 |
2005-09-08 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
治療剤を全身搬送するための中央気道投与
|
|
JP2005521429A
(ja)
|
2002-03-25 |
2005-07-21 |
ユーエービー リサーチ ファウンデーション |
Ｆｃレセプターホモログ、試薬およびこれらの使用
|
|
CA2481658A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to fcy receptor iiia
|
|
EP1354600A1
(en)
|
2002-04-19 |
2003-10-22 |
Affimed Therapeutics AG |
Antibody combination useful for tumor therapy
|
|
WO2004004798A2
(en)
|
2002-07-03 |
2004-01-15 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
|
EP1572091A4
(en)
|
2002-07-09 |
2008-03-05 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
|
|
DK1534335T4
(en)
*
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
|
WO2004022717A2
(en)
|
2002-09-05 |
2004-03-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
|
|
EP1539811A4
(en)
|
2002-09-16 |
2006-05-24 |
Elusys Therapeutics Inc |
PREPARATION OF BISPEQIFIC MOLECULES WITH POLYETHYLENE GLYCOL LINKER
|
|
DK1562972T3
(da)
|
2002-10-15 |
2010-12-06 |
Facet Biotech Corp |
Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
|
|
US7217797B2
(en)
*
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US7361740B2
(en)
*
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
US7960512B2
(en)
*
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
MXPA05010555A
(es)
|
2003-04-04 |
2006-03-09 |
Genentech Inc |
Formulaciones de proteina y anticuerpo de alta concentracion.
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
CN1816356A
(zh)
*
|
2003-05-14 |
2006-08-09 |
免疫原公司 |
药物缀合物组合物
|
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
|
JP2007501021A
(ja)
|
2003-05-30 |
2007-01-25 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
遺伝子操作された定常領域を含む、抗体および融合タンパク質
|
|
JP2008501621A
(ja)
*
|
2003-05-31 |
2008-01-24 |
マイクロメット アクツィエン ゲゼルシャフト |
Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
|
|
ATE385806T1
(de)
|
2003-06-12 |
2008-03-15 |
Lilly Co Eli |
Fusionsproteine
|
|
NZ544924A
(en)
|
2003-06-27 |
2009-03-31 |
Biogen Idec Inc |
Modified binding molecules comprising connecting peptides
|
|
WO2005005604A2
(en)
*
|
2003-06-30 |
2005-01-20 |
Centocor, Inc. |
Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
|
|
HRP20170342T1
(hr)
*
|
2003-07-24 |
2017-05-19 |
Innate Pharma S.A. |
Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice
|
|
CA2533593A1
(en)
|
2003-07-26 |
2005-02-10 |
Biogen Idec Ma Inc. |
Altered antibodies having improved antigen-binding affinity
|
|
CA2534639C
(en)
*
|
2003-07-31 |
2013-07-30 |
Immunomedics, Inc. |
Anti-cd19 antibodies
|
|
EP2434420A3
(en)
|
2003-08-01 |
2012-07-25 |
Dna Twopointo Inc. |
Systems and methods for biopolymer engineering
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
AU2004273791A1
(en)
|
2003-09-05 |
2005-03-31 |
Genentech, Inc. |
Antibodies with altered effector functions
|
|
CA2579635A1
(en)
|
2003-09-10 |
2005-03-17 |
Baxter International Inc. |
Peptides that inhibit complement activation
|
|
WO2005037867A1
(en)
|
2003-10-15 |
2005-04-28 |
Pdl Biopharma, Inc. |
ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
US10000574B2
(en)
|
2003-11-28 |
2018-06-19 |
Amgen Research (Munich) Gmbh |
Compositions comprising polypeptides
|
|
SI1706424T1
(sl)
|
2004-01-12 |
2010-01-29 |
Applied Molecular Evolution |
Variante fc regij
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
KR100545720B1
(ko)
|
2004-05-31 |
2006-01-24 |
메덱스젠 주식회사 |
당화된 면역글로불린 및 이를 포함하는 면역접합체
|
|
MX2007000891A
(es)
|
2004-07-23 |
2007-04-18 |
Genentech Inc |
Cristalizacion de anticuerpos o fragmentos de ellos.
|
|
WO2006047350A2
(en)
*
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
HUE025945T2
(en)
|
2005-02-15 |
2016-07-28 |
Univ Duke |
Anti-CD19 antibodies and their applications in oncology
|
|
EP1885755A4
(en)
|
2005-05-05 |
2009-07-29 |
Univ Duke |
CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
|
|
JP2008546647A
(ja)
|
2005-06-08 |
2008-12-25 |
デューク ユニバーシティ |
移植のための抗−ｃｄ１９抗体治療
|
|
CA2611814A1
(en)
|
2005-06-20 |
2007-01-04 |
Medarex, Inc. |
Cd19 antibodies and their uses
|
|
HRP20150175T1
(en)
|
2005-12-16 |
2015-03-27 |
Amgen Research (Munich) Gmbh |
Means and methods for the treatment of tumorous diseases
|
|
ES2365046T3
(es)
|
2005-12-30 |
2011-09-21 |
Merck Patent Gmbh |
Anticuerpos anti-cd19 con inmunogenicidad reducida.
|
|
US20070166306A1
(en)
|
2006-01-17 |
2007-07-19 |
Fey Georg H M |
Anti-CD19 antibody composition and method
|
|
US20070178103A1
(en)
|
2006-01-30 |
2007-08-02 |
Fey Georg H |
CD19-specific immunotoxin and treatment method
|
|
PL2383297T3
(pl)
*
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
RU2495882C2
(ru)
|
2006-09-08 |
2013-10-20 |
Медиммун, Ллк. |
Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
|
|
US20080267977A1
(en)
|
2007-04-26 |
2008-10-30 |
Friedrich-Alexander University Of Erlangen-Nuremberg |
Combined immunological agent and sensitizing agent for the treatment of cancer
|
|
EP2176298B1
(en)
*
|
2007-05-30 |
2017-11-15 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
US9098105B2
(en)
|
2012-08-24 |
2015-08-04 |
Avago Technologies General Ip (Singapore) Pte. Ltd. |
Dynamic Y-buffer size adjustment for retained sector reprocessing
|
|
US9679104B2
(en)
|
2013-01-17 |
2017-06-13 |
Edico Genome, Corp. |
Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform
|
|
US9703321B2
(en)
|
2013-07-09 |
2017-07-11 |
I-Blades, Inc. |
Snap on wearable module
|
|
US9209965B2
(en)
|
2014-01-14 |
2015-12-08 |
Microsemi Semiconductor Ulc |
Network interface with clock recovery module on line card
|
|
US11392902B2
(en)
|
2017-06-06 |
2022-07-19 |
United Parcel Service Of America, Inc. |
Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery
|
|
KR102185854B1
(ko)
|
2017-09-09 |
2020-12-02 |
애플 인크. |
생체측정 인증의 구현
|